Noworolski, S. M., Vigneron, D. B., Chen, A. P. & Kurhanewicz, J. Dynamic contrast-enhanced MRI and MR diffusion imaging to distinguish between glandular and stromal prostatic tissues. Magn. Reson. Imaging 26, 1071-1080

University of California, Berkeley, Berkeley, California, United States
Magnetic Resonance Imaging (Impact Factor: 2.09). 06/2008; 26(8):1071-80. DOI: 10.1016/j.mri.2008.01.033
Source: PubMed

ABSTRACT To compare peak enhancement (PE), determined from dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) and the magnetic resonance (MR) directionally-averaged apparent diffusion coefficient ( ) in glandular versus stromal prostatic tissues and, with this comparison, to infer if the hypothesis that gadolinium-DTPA (Gd-DTPA) does not enter healthy glands or ducts is plausible.
MRI, MR spectroscopic imaging, DCE MRI and MR diffusion were evaluated in 17 untreated subjects with suspected or proven prostate cancer. PE and were compared in glandular-ductal tissues [normal peripheral zone and glandular benign prostatic hyperplasia (BPH)] and stromal-low ductal tissues (central gland/mixed BPH and stromal BPH).
The glandular-ductal tissues had lower PE [125+/-6.4 (% baseline)] and higher [1.57+/-0.15 (s/10(-3) mm2)] than the stromal-low ductal tissues [PE=132+/-5.5 (% baseline) (P< .0008), =1.18+/-0.20 (s/10(-3) mm2) (P< 1 x 10(-8))]. A statistical model based upon stepwise regression was generated and completely separated the tissue types: ductal Measure = 448+669 x (s/10(-3) mm2)-10.7 x PE (1/%), R2=1.0 and P<8 x 10(-10).
The very different MR results in the glandular-ductal versus stromal-low ductal tissues suggest that these tissues have different underlying structure. These results support the hypothesis that Gd-DTPA does not enter healthy prostatic glands or ducts. This may explain the higher PE and lower that previously have been reported in prostate cancer versus healthy tissue.

13 Reads
  • Source
    • "Although there are no results in the literature regarding the predictive role of Ktrans in the treatment response in NSCLC subtypes, its predictive role in colorectal cancer [20] and colorectal liver metastases have been reported [21]. Ve mainly reflects the cellularity of tumor tissue [22], [23]. Histologically, AC characteristically shows a replacement growth pattern in which cylindric tumor cells grow on the walls of preexisting alveoli, with preservation of the underlying architecture of the lung [24], whereas SCC shows a largely solid growth pattern, with malignant cells proliferating compressively and expansively without a replacement growth pattern [25]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: To prospectively examine the relation between tumor vascularity and glucose metabolism in adenocarcinoma (AC) and squamous cell carcinoma(SCC) of the lung by using positron emission tomography/computed tomography (PET/CT) and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). Forty-one consecutive patients with histologically confirmed untreated NSCLC underwent routine diagnostic work-up, including DCE-MRI and PET/CT. PET/CT images were used to derive glucose metabolism (SUVmax and SUVmean), and DCE-MRI images were used to derive tumor vascularity (Ktrans, Kep, Ve and iAUC). Any differences in the DCE-MRI and PET/CT estimations between the NSCLC subtypes were determined by the Wilcoxon rank sum test. Spearman's rank correlation coefficients were calculated between the DCE-MRI parameter values and the SUV. SUVmean and SUVmax in AC were significantly lower than in SCC, but Ktrans and Ve in AC were significantly higher than in SCC. Significant correlations between SUV and DCE-MRI parameters were observed for SUVmax and Ve (ρ = -0.357, P = 0.022), SUVmean and Ktrans (ρ = -0.341, P = 0.029), and SUVmean and iAUC (ρ = -0.374, P = 0.016 ) in total; for SUVmax and iAUC (ρ = -0.420, P = 0.037), SUVmean and Ktrans (ρ = -0.411, P = 0.041), SUVmean and Kep (ρ = -0.045, P = 0.026), and SUVmean and iAUC (ρ = -0.512, P = 0.009) in AC; However, for neither in SCC. AC and SCC showed different patterns in both tumor vascularity and glucose metabolism. Tumor vascularity and glucose metabolism negatively correlated in AC, but not in SCC. These differences may underlie the heterogeneity in clinical aspect of NSCLC subtypes and have implications for their imaging profiling and monitor the treatment response.
    PLoS ONE 03/2014; 9(3):e91649. DOI:10.1371/journal.pone.0091649 · 3.23 Impact Factor
  • Source
    • "Furthermore, this may be exacerbated by tumor growth impeding the luminal space [29]. This process is summarized on the right side of Fig. 2. Increased cell proliferation requires increased membraneogenesis and choline metabolites, reflected by increased choline and creatine levels in the PZ in PCa [36]. Although citrate, choline, and creatine in prostate biofluids and biopsies may be specific for prostate cancer, appropriate clinical utilization of their relationships to malignant progression is currently limited. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Prostate cancer (PCa) is the most commonly diagnosed visceral cancer in men and is responsible for the second highest cancer-related male mortality rate in Western countries, with increasing rates being reported in Korea, Japan, and China. Considering the low sensitivity of prostate-specific antigen (PSA) testing, it is widely agreed that reliable, age-independent markers of the presence, nature, and progression of PCa are required to facilitate diagnosis and timely treatment. Metabolomics or metabonomics has recently emerged as a novel method of PCa detection owing to its ability to monitor changes in the metabolic signature, within biofluids or tissue, that reflect changes in phenotype and function. This review outlines the physiology of prostate tissue and prostatic fluid in health and in malignancy in relation to metabolomics as well as the principles underlying the methods of metabolomic quantification. Promising metabolites, metabolic profiles, and their correlation with the presence and stage of PCa are summarized. Application of metabolomics to biofluids and in vivo quantification as well as the direction of current research in supplementing and improving current methods of detection are discussed. The current debate in the urology literature on sarcosine as a potential biomarker for PCa is reviewed and discussed. Metabolomics promises to be a valuable tool in the early detection of PCa that may enable earlier treatment and improved clinical outcomes.
    Korean journal of urology 02/2011; 52(2):79-89. DOI:10.4111/kju.2011.52.2.79
  • [Show abstract] [Hide abstract]
    ABSTRACT: The diagnosis and management of carcinoma of the prostate, the most common neoplasm affecting men ( apart from basal cell and squamous skin cancer) remains controversial. Separating the indolent from the biologically aggressive tumors poses a major challenge. As with all malignancies, imaging is expected to detect early and stage accurately the important tumors, evaluate for possible recurrence or metastases and establish the efficacy of the chosen treatment. The important role of magnetic resonance imaging (MRI) in the detection, staging, and follow up of prostate carcinoma is well established. This chapter discusses pertinent anatomic, clinical, biochemical, and imaging facts regarding diseases of the prostate, with emphasis on the MRI contribution. Topics include discussion on the appropriate use and interpretation of dynamic contrast enhanced MRI, diffusion imaging, and magnetic resonance spectroscopic imaging in the management of benign and malignant diseases, primarily cancer.
    Clinical MRI of the Abdomen, 01/2009: pages 559-598; , ISBN: 978-3-540-85688-7
Show more


13 Reads
Available from